Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Condylomata Acuminata 1Cancer Survivor 1

Interventions

pembrolizumab 6Cisplatin 5Radiotherapy 4Paclitaxel 3Nivolumab 3lenvatinib 2Specimen Handling 2Platinum 2Papillomavirus Vaccines 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Gemcitabine 2Carboplatin 2CTLA-4 Antigen 2Bleomycin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cemiplimab 1belzutifan 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1aldesleukin 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vulvar Neoplasms × Vaccines, Synthetic × Clear all
NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
620 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡